Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Chemotherapy + Apatinib in Advanced NSCLC
NCT04950400Phase 2Unknown
- Sponsor
- Beijing Chest Hospital
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Beijing Chest Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04950400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950400.